R R

What Is Chimeric Antigen Receptor T-Cell Therapy?

Chimeric antigen receptor T-cell therapy is an immune-cell treatment in which T lymphocytes are genetically modified to recognize a selected target on cancer cells. It is commonly called CAR T-cell therapy. The engineered receptor combines an antigen-binding region with signaling components that activate the T cell. After infusion, the cells can multiply, find target-bearing cells, and destroy them.

Link to This Resource Page

Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.

To display this...

What Is Chimeric Antigen Receptor T-Cell Therapy?

Chimeric antigen receptor T-cell therapy is an immune-cell treatment in which T lymphocytes are genetically modified to recognize a selected target on cancer cells. It is commonly called CAR T-cell therapy. The engineered receptor combines an antigen-binding region with signaling components that activate the T cell. After infusion, the cells can multiply, find target-bearing cells, and destroy them.

read more about chimeric antigen receptor tcell therapy ...

Copy this HTML:

Copy HTML Copied!

What Is CAR T-Cell Therapy Used For?

Approved CAR T-cell products treat selected leukemias, lymphomas, and multiple myeloma that meet product-specific criteria. Common targets include CD19 on B-cell cancers and B-cell maturation antigen on plasma-cell cancers. The therapy is usually considered after certain prior treatments, although approved treatment lines continue to evolve. CAR T-cell therapy is being studied for additional blood cancers, solid tumors, autoimmune diseases, and other conditions.

How Is CAR T-Cell Therapy Made and Given?

T cells are collected from the patient or, in investigational settings, can come from a donor source. A laboratory introduces genetic instructions for the chimeric antigen receptor and expands the modified cells. Patients commonly receive lymphodepleting chemotherapy before the CAR T-cell infusion. Manufacturing, testing, conditioning treatment, infusion, and follow-up are coordinated through an authorized treatment center.

How Does CAR T-Cell Therapy Work?

The receptor binds a specific antigen on the surface of a target cell without relying on the usual antigen-presentation process. Binding activates the engineered T cell and triggers killing through cytotoxic proteins and immune signaling. CAR T cells can expand greatly after infusion and can persist for months or longer. Cancer cells can escape treatment by losing the target antigen or developing other resistance mechanisms.

What Are the Side Effects and Monitoring Needs?

Cytokine release syndrome can cause fever, low blood pressure, low oxygen, organ dysfunction, or life-threatening inflammation. Immune effector cell-associated neurotoxicity syndrome can cause confusion, language difficulty, tremor, seizures, weakness, or cerebral edema. Other risks include prolonged low blood-cell counts, serious infection, low immunoglobulin levels, tumor lysis syndrome, and secondary malignancies. Patients require close early monitoring and long-term follow-up under product-specific safety requirements.

Frequently Asked Questions About CAR T-Cell Therapy

Is CAR T-cell therapy chemotherapy?

No. It is a cellular immunotherapy, although lymphodepleting chemotherapy is commonly given before the modified T cells are infused.

Is CAR T-cell therapy made from the patient's own cells?

Currently approved products commonly use the patient's own T cells. Donor-derived and ready-made cellular products are also being studied.

What is cytokine release syndrome?

It is a systemic inflammatory reaction caused by rapid immune activation and cytokine release. Severity ranges from fever alone to life-threatening organ dysfunction.

Can CAR T-cell therapy stop working?

Yes. Cancer can recur when target antigens are lost, CAR T cells do not persist, or other resistance mechanisms develop.

References

ELIQUIS (Apixaban) Tablets: Prescribing Information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1523ab32-2c2c-6501-e063-6394a90aa0b3. Date Accessed August 6, 2026.

XARELTO (Rivaroxaban) Tablets and Oral Suspension: Prescribing Information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10db92f9-2300-4a80-836b-673e1ae91610. Date Accessed August 6, 2026.

PRADAXA (Dabigatran Etexilate) Capsules: Prescribing Information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=80637981-d5a7-48cb-b7b2-f50807a8ab20. Date Accessed August 6, 2026.

SAVAYSA (Edoxaban) Tablets: Prescribing Information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e77d3400-56ad-11e3-949a-0800200c9a66. Date Accessed August 6, 2026.

PRAXBIND (Idarucizumab) Injection: Prescribing Information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c7400f8a-dcf4-a6df-6d07-983081b1bf34. Date Accessed August 6, 2026.